Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc (ELTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Elicio Therapeutics Presents Encouraging Updated Phase 1 Data for ELI-002 Cancer Vaccine at ESMO Immuno-Oncology Congress 2024 Quiver Quantitative, Inc. - Thu Dec 12, 4:20PM CST

Elicio Therapeutics presented positive Phase 1 results for ELI-002, targeting KRAS mutations in high-risk cancer patients.Quiver AI SummaryElicio Therapeutics presented updated Phase 1 data for its cancer...

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 GlobeNewswire - Thu Dec 12, 6:00AM CST

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment GlobeNewswire - Tue Dec 3, 6:00AM CST

ELTX : 5.24 (+4.17%)
Elicio Therapeutics: Q3 Earnings Snapshot AP - Wed Nov 13, 3:23PM CST

Elicio Therapeutics: Q3 Earnings Snapshot

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates GlobeNewswire - Wed Nov 13, 3:05PM CST

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting GlobeNewswire - Thu Nov 7, 3:05PM CST

ELTX : 5.24 (+4.17%)
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit GlobeNewswire - Thu Oct 31, 7:30AM CDT

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Reports Inducement Grants GlobeNewswire - Wed Oct 16, 7:30AM CDT

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies Prodigy - Wed Apr 24, 9:15AM CDT

Boston, Massachusetts () April 24, 2024 -- Elicio Therapeutics, a clinical biotechnology company, commemorates its 13th anniversary of innovative medical research into cancer vaccines.

ELTX : 5.24 (+4.17%)

Barchart Exclusives

Unusual Options Volume in Palantir Puts Could Signal a Stock Peak Barchart - Wed Dec 25, 12:30PM CST
A huge, unusual volume in Palantir Technologies put options may signal a near-term peak in PLTR stock. It has doubled since its Q3 earnings on Nov. 4. However, put premiums are now very high—an income play for short-sellers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot